Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
ALL MEDICAL CODES IN CATEGORY Q5112-Q5134

2025 HCPCS code Q5126

Injection, bevacizumab-maly, biosimilar, (Alymsys), 10 mg

2025 HCPCS code Q5117

Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg

2025 HCPCS code Q5119

Rituximab-pvvr injection, 10 mg

2025 HCPCS code Q5127

Injection, pegfilgrastim-fpgk (Stimufend), biosimilar, 0.5 mg; a leukocyte growth factor used to reduce infection risk in patients undergoing myelosuppressive chemotherapy.

2025 HCPCS code Q5114

Injektion, Trastuzumab-DKST, Biosimilar, (Ogivri), 10 mg

2025 HCPCS code Q5114

Injeksyon, trastuzumab-dkst, biosimilar, (Ogivri), 10 mg

2025 HCPCS code Q5114

Injection, trastuzumab-dkst, biosimilar, (Ogivri), 10 mg

2025 HCPCS code Q5125

Filgrastim-ayow, biosimilar, (Releuko®) injection, 1 mcg

2025 HCPCS code Q5127

Inyección, pegfilgrastim-fpgk (Stimufend), biosimilar, 0,5 mg; un factor de crecimiento leucocitario que se utiliza para reducir el riesgo de infección en pacientes sometidos a quimioterapia mielosupresora.

2025 HCPCS code Q5127

حقن، pegfilgrastim-fpgk (Stimufend)، بديل حيوي، 0.5 ملجم؛ عامل نمو كريات الدم البيضاء يُستخدم لتقليل خطر العدوى لدى المرضى الذين يخضعون للعلاج الكيميائي المثبط للنقي.

2025 HCPCS code Q5114

Tiêm, trastuzumab-dkst, tương tự sinh học, (Ogivri), 10 mg

2025 HCPCS code Q5127

注射剂,pegfilgrastim-fpgk(Stimufend),生物仿制药,0.5 mg;一种白细胞生长因子,用于降低接受骨髓抑制性化疗的患者的感染风险。

2025 HCPCS code Q5127

주사제, 페그필그라스팀-fpgk (Stimufend), 바이오시밀러, 0.5mg; 골수억제 화학요법을 받는 환자의 감염 위험을 줄이기 위해 사용되는 백혈구 성장 인자.

2025 HCPCS code Q5127

Injection, pegfilgrastim-fpgk (Stimufend), biosimilaire, 0,5 mg ; facteur de croissance des leucocytes utilisé pour réduire le risque d'infection chez les patients subissant une chimiothérapie myélosuppressive.

2025 HCPCS code Q5127

Injection, pegfilgrastim-fpgk (Stimufend), biosimilar, 0.5 mg; isang leukocyte growth factor na ginagamit upang mabawasan ang panganib ng impeksiyon sa mga pasyente na sumasailalim sa myelosuppressive therapy.

2025 HCPCS code Q5127

Injektion, Pegfilgrastim-fpgk (Stimufend), Biosimilar, 0,5 mg; ein Leukozytenwachstumsfaktor zur Verringerung des Infektionsrisikos bei Patienten, die sich einer myelosuppressiven Chemotherapie unterziehen.

2025 HCPCS code Q5127

Tiêm, pegfilgrastim-fpgk (Stimufend), tương tự sinh học, 0,5 mg; một yếu tố tăng trưởng bạch cầu được sử dụng để giảm nguy cơ nhiễm trùng ở những bệnh nhân đang trải qua hóa trị ức chế tủy.

2025 HCPCS code Q5126

حقن، بيفاسيزوماب مالي، بديل حيوي، (Alymsys)، 10 ملغ

2025 HCPCS code Q5125

فيلغراستيم-أيوو، بديل حيوي، حقن (Releuko®)، 1 ميكروغرام

2025 HCPCS code Q5125

Filgrastim-AYOW, Biosimilar, (Releuko®) -Injektion, 1 mcg

2025 HCPCS code Q5125

필그라스팀-아요우, 바이오시밀러, (릴레오코®) 주사, 1mcg

2025 HCPCS code Q5126

Bevacizumab-maly, biosimilaire, injection, (Alymsys), 10 mg

2025 HCPCS code Q5126

Injektion, Bevacizumab-Maly, Biosimilar, (Alymsys), 10 mg

2025 HCPCS code Q5126

Inyección, bevacizumab-mali, biosimilar, (Alymsys), 10 mg

2025 HCPCS code Q5126

주사제, 베바시주맙말리, 바이오시밀러, (알림시스), 10mg

2025 HCPCS code Q5126

Injeksyon, bevacizumab-maly, biosimilar, (Alymsys), 10 mg

2025 HCPCS code Q5125

Filgrastim-AYOW, biosimilaire, injection (Releuko®), 1 mcg

2025 HCPCS code Q5126

Thuốc tiêm, bevacizumab-maly, biosimilar, (Alymsys), 10 mg

2025 HCPCS code Q5125

Filgrastim-AYOW, biosimilar, inyección (Releuko®), 1 mcg

2025 HCPCS code Q5126

注射剂,bevacizumab-maly,生物仿制药,(Alymsys),10 mg

2025 HCPCS code Q5125

Filgrastim-AYOW,生物仿制药,(Releuko®)注射剂,1 mcg

2025 HCPCS code Q5125

Thuốc tiêm Filgrastim-AYOW, tương tự sinh học, (Releuko®), 1 mcg

2025 HCPCS code Q5125

Filgrastim-Ayow, biosimilar, (Releuko®) iniksyon, 1 mcg

2025 HCPCS code Q5114

Trastuzumab-Dkst, biosimilaire, injection (Ogivri), 10 mg

2025 HCPCS code Q5114

حقن، تراستوزوماب-دوكست، بديل حيوي، (أوجيفري)، 10 ملغ

2025 HCPCS code Q5114

주사제, 트라스투주맙-DKST, 바이오시밀러, (오기브리), 10mg

2025 HCPCS code Q5119

리툭시맙-PVVR 주사, 10 밀리그램

2025 HCPCS code Q5119

Tiêm rituximab-PVVR, 10 mg

2025 HCPCS code Q5119

利妥昔单抗-PVVR 注射液,10 mg

2025 HCPCS code Q5119

Inyección de rituximab-PVVR, 10 mg

2025 HCPCS code Q5119

Iniksyon ng Rituximab-PVVR, 10 mg

2025 HCPCS code Q5119

Rituximab-PVVR pour injection, 10 mg

2025 HCPCS code Q5119

Rituximab-PVVR-Injektion, 10 mg

2025 HCPCS code Q5119

حقن ريتوكسيماب-PVVR، 10 ملغ

2025 HCPCS code Q5117

Inyección, trastuzumab, biosimilar, (Kanjinti), 10 mg

2025 HCPCS code Q5117

Trastuzumab-anns, biosimilaire, injection (Kanjinti), 10 mg

2025 HCPCS code Q5117

Tiêm, trastuzumab-anns, tương tự sinh học, (Kanjinti), 10 mg

2025 HCPCS code Q5117

حقن، تراستوزوماب، بديل حيوي، (كانجينتي)، 10 ملغ

2025 HCPCS code Q5117

注射剂,曲妥珠单抗,生物仿制药,(Kanjinti),10 mg

2025 HCPCS code Q5117

Injektion, Trastuzumab-ans, Biosimilar, (Kanjinti), 10 mg